In liver cirrhosis, abnormal liver architecture impairs efficient transduction of hepatocytes with large viral vectors such as adenoviruses. Here we evaluated the ability of adeno-associated virus (AAV) vectors, small viral vectors, to transduce normal and cirrhotic rat livers. Using AAV serotype-1 (AAV1) encoding luciferase (AAV1Luc) we analyzed luciferase expression with a CCD camera. AAV1Luc was injected through the hepatic artery (intra-arterial (IA)), the portal vein (intra-portal (IP)), directly into the liver (intra-hepatic (IH)) or infused into the biliary tree (intra-biliar). We found that AAV1Luc allows long-term and constant luciferase expression in rat livers. Interestingly, IP administration leads to higher expression levels in healthy than in cirrhotic livers, whereas the opposite occurs when using IA injection. IH administration leads to similar transgene expression in cirrhotic and healthy rats, whereas intra-biliar infusion is the least effective route. After 70% partial hepatectomy, luciferase expression decreased in the regenerating liver, suggesting lack of efficient integration of AAV1 DNA into the host genome. AAV1Luc transduced mainly the liver but also the testes and spleen. Within the liver, transgene expression was found mainly in hepatocytes. Using a liver-specific promoter, transgene expression was detected in hepatocytes but not in other organs. Our results indicate that AAVs are convenient vectors for the treatment of liver cirrhosis.
INTRODUCTION
Liver cirrhosis is a consequence of chronic liver damage characterized by death of hepatocytes, which are replaced by fibrous tissue and nodules of regeneration, leading to progressive loss of liver function. Liver transplantation is the only curative option for patients with advanced liver cirrhosis. This procedure can only be applied to a minority of patients owing to contraindications for the operation and scarcity of organs. Therefore, new therapies aimed at halting the progression of liver cirrhosis are urgently needed. Treatment of liver cirrhosis should be directed to attenuating liver injury and inflammation, degrading the excess of collagen in the extracellular matrix, inhibiting the activation of hepatic stellate cells (HSCs), responsible for the synthesis of collagen, 1 and improving liver function. Several authors have shown that these therapeutic effects can be achieved by inducing the expression of specific genes, such as interferon, bone morphogenetic proteins, superoxide dismutase, SPARC, HNF4a, methaloproteinases, urokinase plasminogen activator or insulin-like growth factor I among others, within the liver. [2] [3] [4] [5] [6] [7] [8] [9] [10] In most cases, the liver expression of the therapeutic transgene is obtained by using adenoviral vectors, which have a natural tropism for the liver. However, adenoviral vectors do not transduce cirrhotic livers as efficiently as healthy livers. Adenoviral transduction of cirrhotic rats treated with carbon tetrachloride (CCl 4 ) decreases 2-to 10-fold compared with that of healthy animals. 11, 12 In animals subjected to bile duct ligation, luciferase expression from adenoviral vectors is 10 000-fold lower compared with that of healthy rats. 12 These results have therapeutic relevance as CCl 4 treatment develops a liver disease similar to human alcoholic cirrhosis, whereas bile duct ligation is a model for human biliary cirrhosis. The decreased adenoviral transduction of cirrhotic livers could be caused by the altered liver architecture and the marked accumulation of extracellular matrix characteristic of liver cirrhosis. Theoretically, collagen deposits could act as a filter that decreases the spread and infectivity of viral vectors. Besides, for liver transduction, viral vectors need to cross the sinusoidal fenestrae, whose number decreases in liver cirrhosis. 13 These constraints should more seriously affect the diffusion of large particles, such as adenoviral vectors, which have a diameter of 90-120 nm. 13 Adeno-associated virus (AAV) vectors are small viruses only 20 nm in diameter, which posses several advantages as gene therapy vectors. 14, 15 The bio-safety of AAV vectors has been clearly established in animal models and in clinical trials. Furthermore, several tissues are susceptible for AAV transduction. Tissue specificity depends on the viral capsid proteins and therefore varies with serotype. Several serotypes of AAVs have been isolated that target different tissues and serve for the generation of chimeric or mutated vectors with novel tropisms. Once the viral genome is released in the target cell, conversion of the single-stranded genome to double-stranded DNA is an essential rate-limiting step. To overcome this obstacle, several researchers have developed AAV vectors that package double-stranded DNA genomes (double-stranded AAV (dsAAV)). [16] [17] [18] dsAAV vectors are obtained by mutation of one of the flanking inverted terminal repeats (ITRs) of the viral genome. The drawback of dsAAV is that packaging capacity is drastically reduced. The clear benefit is that transduction from dsAAV is faster and 10-to 20-fold higher than transduction from standard single-stranded AAV (ssAAV). [18] [19] [20] Transgene expression mediated by AAVs can persist for several years in vivo. 21, 22 AAV genomes persist in non-dividing cells as episomal DNAs, but a very low level of integration could also occur. 23 In this study we hypothesize that as AAVs are small vectors, they could transduce cirrhotic livers efficiently. AAV serotype-1 (AAV1) has been shown to transduce rat livers. 24 Therefore, we used AAV1 to analyze vector expression in healthy and cirrhotic animals. Interestingly, expression from AAV1 was similar in healthy animals or in rats where liver cirrhosis was induced by treatment with CCl 4 or thioacetamide (TAA). Several routes that target the liver were used for vector administration, with the aim of establishing the protocol that allows the highest transduction of cirrhotic livers. In all cases a strong and long-lasting expression in the liver was achieved. However, expression was not liver-specific. Liver specificity and preferential expression in hepatocytes were achieved when the transgene was expressed from a liver-specific promoter. Our data point to AAV vectors as convenient tools for the treatment of liver cirrhosis.
RESULTS

Analysis of AAV transduction in rat livers before, during and after liver cirrhosis induction
To address the efficacy of AAV vectors to transduce cirrhotic livers, we first wanted to determine the impact of liver cirrhosis on transgene expression. Thus, we first analyzed transgene expression from AAV vectors in the liver of healthy rats. Then, these animals were treated with CCl 4 to induce liver cirrhosis and transgene expression was evaluated before, during and after the development of cirrhosis. We used AAV2 vectors pseudotyped with serotype-1, which have been reported to transduce rat liver efficiently. 24 Firefly luciferase was used as a transgene, as luciferase activity is linear in a wide range and can be measured in living animals. The vector of choice was dsAAV1-PBGDLuc, which expresses luciferase from a ubiquitous porphobilinogen deaminase promoter (PBGD) and contains a double-stranded genome (Figure 1a) . 20 We considered that transduction of AAV vectors could be different depending on the route of administration used for viral entry. Therefore, we introduced 3.4Â10 10 viral genomes of dsAAV1-PBGD-Luc through the hepatic artery (n¼6), the portal vein (n¼6) or by direct injection into the liver (n¼6). Eight weeks after vector administration, liver cirrhosis was induced in these animals by treatment with CCl 4 (Supplementary Figure 1) . This treatment has a mortality of 35%, which was distributed homogeneously among the groups and reduced the number of animals per group to 4. The remaining animals survived until being killed 8 weeks after the last administration of CCl 4 . Luciferase expression was analyzed every 7 or 15 days throughout the experimental protocol except during cirrhosis induction, when it was analyzed only once ( Figure 1b) . The results show that luciferase expression in vivo was only detected in the hepatic area (Figure 2a ). High levels of luciferase expression were detected in all the animals, indicating a good transduction by the viral vector (Figure 2b) . Interestingly, luciferase expression tended to be higher in those animals in which dsAAV1-PBGD-Luc was administered intrahepatically or into the portal vein than in rats that received the virus through the hepatic artery. Transgene expression was detected throughout the experimental protocol. Expression levels showed a mild decrease before, during and after cirrhosis induction in these animals. This indicates that development and establishment of liver cirrhosis do not have a large impact on expression from AAV vectors. This is not surprising as the hepatic regeneration that accompanies liver cirrhosis is mild. 25 
Analysis of AAV transduction in CCl 4 -treated cirrhotic livers
We evaluated the capacity of AAV vectors to transduce a cirrhotic liver. First, liver cirrhosis was induced by intra-gastric administration of CCl 4 during 8 weeks (Supplementary Figure 1) . Then we injected 3.4Â10 10 viral genomes of dsAAV1-PBGD-Luc into the hepatic artery (intraarterial (IA)) (n¼6), the portal vein (intra-portal (IP)) (n¼6), the biliary duct (intra-biliar) (n¼5) or by direct intra-hepatic administration (IH) (n¼4). After surgery, all animals survived until the end of the experiment. Luciferase expression was measured once a week for 14 weeks (Figure 1c ). Again, high levels of luciferase expression were detected in the hepatic area, indicating good liver transduction by the viral vector ( Figure 3a ). Transgene expression was detected throughout the experimental protocol ( Figure 3b ). Luciferase expression tended to be higher in animals injected by the IA or IH route than in those that received the vector by IP injection. A statistically significant lower expression was observed in animals in which the virus was administered by intra-biliar infusion compared with animals injected IA or IH (Figure 3c ).
When we compared luciferase expression in healthy and cirrhotic livers we found that the levels were similar when using the IH route (Figure 3d ). However, IP administration led to higher expression levels in healthy rats than in cirrhotic animals, whereas the IA route led to higher expression levels in cirrhotic rats than in healthy animals.
Analysis of luciferase expression from AAV vectors after hepatectomy
The genome of AAV vectors is maintained episomically in transduced cells. However, a small proportion could be integrated into the host genome. 26 If integration of the vector DNA occurs with high efficiency in our model, the viral genome should be transferred from mother to daughter cells during liver regeneration. Therefore, luciferase expression should be constant even when the liver has completed regeneration after hepatectomy. To determine whether this was the case, 3.4Â10 10 viral genomes of dsAAV1-PBGD-Luc were injected into healthy (n¼7) or CCl 4 -treated cirrhotic rats (n¼10). The vector was administered by IA injection except in four cirrhotic animals in which it was administered by the IH route. Four weeks after vector administration in healthy animals and 18 weeks after vector administration in cirrhotic animals, 70% hepatectomy was performed in half of the animals. The remaining rats were used as controls. Luciferase expression was measured the day before hepatectomy, considered as day 0, and then once a week or every 2 weeks. Luciferase expression was found to decrease by 70% after liver regeneration that follows hepatectomy (Figure 4) . The decrease in transgene expression was similar in healthy and cirrhotic animals. These results are in agreement with a preferential episomal maintenance of the viral genome, which is diluted when hepatocytes replicated following hepatectomy.
Bio-distribution of dsAAV1-PBGD-Luc in cirrhotic animals
Although we have injected the AAV vector by IH, IA or IP routes, we cannot exclude the possibility that a percentage of the vector dose could escape from the liver. This vector could be distributed systemically and transduce other organs. To evaluate extra-hepatic transgene expression, the animals that were transduced with dsAAV1-PBGD-Luc after cirrhosis induction were killed at the end of the protocol and luciferase activity was evaluated in vitro in extracts obtained from the brain, lung, heart, gut, stomach, muscle, kidney, testes, spleen and liver ( Figure 1c ). Our data showed that, although luciferase expression can be detected preferentially in the liver, low levels of luciferase activity could also be detected in the testes and spleen (Figure 5a ).
To determine which liver cell subpopulations express the transgene, cirrhotic animals (n¼7) were injected through the hepatic artery with 3.4Â10 10 genomes of dsAAV1-PBGD-Luc and luciferase expression was verified with a CCD camera (data not shown). Twelve weeks after vector inoculation, hepatocytes, HSCs and a mixture of Kupffer and endothelial cells were isolated from the liver of these animals. Non-transduced animals were also used to isolate control liver cells. Cells extracts were used to evaluate luciferase expression or to determine AAV genomes by quantitative PCR (Figures 5b and c) . Luciferase expression and AAV genomes were predominantly detected in hepatocytes, but also in Kupffer-endothelial cells. Luciferase expression in HSCs was very low and AAV genomes could not be detected above background levels in these liver cells.
Analysis of transduction of cirrhotic livers with an AAV vector that contains a liver-specific promoter
The results obtained indicate that AAV vectors transduce cirrhotic livers efficiently. However, in spite of targeting the vector to the liver Figure 3 Analysis of luciferase expression in CCl 4 -treated cirrhotic rats transduced by dsAAV1-PBGD-Luc. Liver cirrhosis was induced by treatment with CCl 4 for 8 weeks. Then, cirrhotic animals were inoculated with 3.4Â10 10 genomes of dsAAV1-PBGD-Luc through the hepatic artery (intra-arterial (IA)), the portal vein (intra-portal (IP)), the bile duct (intra-biliar) or by direct intra-hepatic administration (IH). Luciferase expression was evaluated with a CCD camera once a week during 100 days after vector administration. Representative images taken 14 days after vector administration are shown with the same color scale (a). Quantification of luciferase expression during the complete experimental protocol has been plotted (b). Quantification of luciferase expression detected 14 days after vector administration is shown as bars (c). The error bars represent standard deviations. A P-value o0.05 was considered significant (*). A comparison between luciferase expression in healthy and cirrhotic livers is also shown (d). Standard deviations were lower than 30% and are not indicated in all cases for simplicity.
by the type of injection used, transgene expression could be detected in extra-hepatic tissues. Liver specificity is desirable for the gene therapy treatment of chronic liver diseases. Therefore, we decided to test the expression and the bio-distribution of an AAV vector in which luciferase expression was under a liver-specific promoter. To this aim we made use of an AAV vector that drives luciferase expression from a chimeric promoter that fuses the albumin enhancer to the a-1 antitrypsin promoter (EhAlbAAT). We have shown previously that expression from EhAlbAAT is liver-specific in mice. 27 Unfortunately, the size of this promoter fused to luciferase and termination sequences exceeded the cloning capacity of dsAAV vectors. Therefore we had to use a single-stranded AAV vector named ssAAV1-EhAlbAAT-Luc (Figure 1a) . 28 To gauge ssAAV1-EhAlbAAT-Luc transgene expression in rat cirrhotic liver, liver cirrhosis was induced with CCl 4 . We then injected into the hepatic artery 1.2Â10 12 (n¼12), 2.4Â10 11 (n¼12), 4.8Â10 10 (n¼12) or 9.7Â10 9 genomes (n¼12) of ssAAV1-EhAlbAAT-Luc or 3.4Â10 9 genomes of dsAAV1-PBGD-Luc as control (n¼7). Luciferase expression was evaluated with a CCD camera at 4 days after vector injection and weekly for 8 weeks. The results show that luciferase expression was exclusively found over the hepatic region (data not shown). Luciferase expression was detected in all the animals at 4 days after vector injection and was constant until the end of the experiment ( Figure 6 ). Note that a direct comparison between ssAAV1-EhAlbAAT-Luc and dsAAV1-PBGD-Luc cannot be made as both vectors have different promoters and different genomes. In the case of high doses of ssAAV1-EhAlbAAT-Luc, there was a good correlation between the luciferase levels and the doses used. Thus, animals transduced with 1.2Â10 12 genomes expressed five times more luciferase than animals that received 2.4Â10 11 genomes.
Bio-distribution of ssAAV1-EhAlbAAT-Luc in cirrhotic animals
At the end of the previous study, cirrhotic animals treated with 4.8Â10 10 genomes of ssAAV1-EhAlbAAT-Luc were killed and a bio-distribution study was performed. Luciferase activity was Figure 5 Analysis of luciferase expression in extracts from cirrhotic animals treated with dsAAV1-PBGD-Luc. The animals described in Figure 3 were killed and luciferase activity was quantified in vitro from extracts obtained from the indicated organs (a) or from purified hepatocytes (Hepato), HSCs or Kupffer and endothelial cells (KC-EC) (b). Luciferase was also evaluated in liver cells from control animals. Viral DNA was quantified from liver cells by quantitative PCR (c) using oligonucleotides that amplify the luciferase gene (luciferase) or the PBGD promoter (PBGD). The background levels obtained in liver cells isolated from control animals is also indicated. The error bars indicate standard deviations. Figure 4 Analysis of luciferase expression in hepatectomized and control animals transduced by dsAAV1-PBGD-Luc. Liver cirrhosis was induced by treatment with CCl 4 for 8 weeks. Then, healthy and cirrhotic animals were inoculated with 3.4Â10 10 genomes of dsAAV1-PBGD-Luc through the hepatic artery (intraarterial (IA)). Cirrhotic animals were also inoculated by direct intra-hepatic administration (IH). Four weeks after vector administration in healthy animals and 18 weeks after vector administration in cirrhotic animals, half of the animals were subjected to a hepatectomy of 70% of the liver. Luciferase expression was evaluated with a CCD camera once a week during 8 weeks after hepatectomy. Representative images taken 30 days after surgery from control (Mock) or hepatectomized (Hepa) animals are shown with the same color scale (a). Quantification of luciferase expression from healthy (b) and cirrhotic (c) animals during all the experimental protocol is also shown. Quantification of luciferase expression detected 49 days after hepatectomy is shown as bars (d). The error bars represent standard deviations, which were lower than 30% and are not indicated in all cases for simplicity. evaluated in vitro in extracts obtained from the brain, lung, heart, gut, stomach, muscle, kidney, testes, spleen and liver. Luciferase expression was detected exclusively in the liver (Figure 7a ). Hepatocytes, HSCs and a mixture of Kupffer and endothelial cells were isolated from the liver of cirrhotic animals treated with 2.4Â10 11 genomes of ssAAV1-EhAlbAAT-Luc and luciferase expression was evaluated from cell extracts. Luciferase expression was predominantly detected in hepatocytes but also in Kupffer-endothelial cells and HSCs (Figure 7b ).
Analysis of AAV transduction in TAA-treated cirrhotic livers
The results obtained so far indicate that ssAAV1-EhAlbAAT-Luc vectors could transduce cirrhotic livers to express high levels of transgene in the liver. However, all experiments were performed in animals in which liver cirrhosis was induced with CCl 4 . Therefore, we evaluated transduction by ssAAV1-EhAlbAAT-Luc in TAA-treated cirrhotic animals, which generally develop more fibrosis (Supplementary Figure 2) . After cirrhosis induction, animals were injected through the hepatic artery with 1.2Â10 12 genomes of ssAAV1-EhAlbAAT-Luc. Luciferase expression was analyzed in these animals with a CCD camera once a week for 8 weeks. The results were compared with the luciferase expression observed in healthy animals injected through the hepatic artery with the same dose of ssAAV1-EhAlbAAT-Luc ( Figure 8) . As was the case with CCl 4 -treated cirrhotic animals, there were no significant differences between the expression of ssAAV1-EhAlbAAT-Luc in healthy and TAA-treated cirrhotic animals.
DISCUSSION
In this study we have compared liver transduction by AAV vectors in healthy and cirrhotic livers in rats. Liver cirrhosis was induced by treatment with either CCl 4 or TAA. Chronic CCl 4 exposure causes hepatocellular damage and progressive liver fibrosis resembling the morphological features observed in cirrhotic livers in humans. Histopathological changes are more prominent in TAA-induced liver cirrhosis 29 as we have observed in the present work ( Supplementary  Figures 1 and 2 ). Other models of liver cirrhosis, such as bile duct ligation, course with lower levels of liver fibrosis (average of 9.5%). In fibrotic livers with fibrosis area 425%, such as those treated with TAA, transduction of hepatic tissue by adenoviral vectors administered systemically is highly inefficient. 11 Adenoviral transduction is also inefficient in the hepatocytes of rats that have developed cirrhosis after CCl 4 treatment or bile duct ligation. 11, 12 Instead, adenovirus transduce sinusoidal cells such as Kupffer cells, HSCs or endothelial cells. 30, 31 It has been suggested that transduction of hepatocytes is affected in cirrhotic livers at the access from the blood to the space of Disse and at the interaction of the vector with the hepatocyte. The passage from the blood into the space of Disse is through the fenestrae of sinusoidal cells. Once the vector is in the space of Disse, it has to bind to the microvillous surface of hepatocytes before transduction. However, liver cirrhosis is characterized by a decreased number of fenestrae, which impedes access to the space of Disse, and a decreased surface of hepatocytes and the presence of collagen fibers that hinders the contact of the vector with the hepatocytes. Restriction to transport of vectors through fenestrae and the space of Disse increases in accordance with the size of the vector. 13 Therefore we tested AAV vectors, which posses a diameter five times lower than adenoviral vectors. Here we show that AAV vectors achieve similar level of hepatic tissue transduction in healthy and cirrhotic rats, with different degrees of liver fibrosis ( Supplementary Figures 1 and 2; Figures 3, 6 and 8 ). This remarkable transduction efficiency of cirrhotic livers was observed with AAV vectors that contain single-or double-stranded genomes.
We found that the transduction of healthy and cirrhotic livers was similar when the AAV vector was injected by the IH route (Figure 3d) . However, transduction efficiency in cirrhotic livers was lower than in healthy livers when the vector was administered by IP injection, in Figure 6 Analysis of luciferase expression in cirrhotic rats transduced with ssAAV1-EhalbAAT-Luc. Liver cirrhosis was induced with CCl 4 , as described. Then, ssAAV1-EhalbAAT-Luc vector was administered through the hepatic artery of cirrhotic animals. Several doses were tested: 1.2Â10 12 , 2.4Â10 11 , 4.8Â10 10 and 9.7Â10 9 genomes per rat. One group of animals received intra-arterial (IA) 3.4Â10 9 genomes per rat of dsAAV1-PBGD-Luc, for comparison. Luciferase expression was evaluated with a CCD camera once a week during 8 weeks. Standard deviations were lower than 30% and are not indicated for simplicity. agreement with the fact that cirrhotic nodules are preferentially irrigated by the hepatic artery and receive less flow by the portal vein. 32 In keeping with the predominance of hepatic artery supply to cirrhotic nodules, we found that the IA route resulted in a higher hepatic tissue transduction in cirrhotic than in healthy livers. These data suggest that the most adequate procedure to be used in cirrhotic patients should be catheterization of the hepatic artery followed by intra-arterial injection of the viral vector.
In addition to transducing the fibrotic liver efficiently, AAV1 vectors allow long-term expression of the transgene. Indeed luciferase activity remained relatively constant throughout the entire experimental period. The AAV genome has been described as episomal in the transduced cell, so regeneration of hepatocytes should lead to the dilution of the viral genome and, therefore, to decreased transgene expression. To address this possibility, we forced liver proliferation by hepatectomy. Seventy percent of the liver was removed from healthy animals (Figures 4a and b) and in rats in which liver cirrhosis had been induced with CCl 4 (Figures 4a, c and d) or with TAA (data not shown). In all cases, after hepatectomy, luciferase expression decreased by 70% compared with control livers: This dilution of transgene expression suggests that the viral DNA has not been integrated efficiently into the cell genome. It seems possible, however, that some viral genomes have been integrated but at levels that cannot be detected by using this technology. Also, efficient integration could have occurred but followed by silencing of the viral genome. Further experiments should be performed to address AAV vector integration.
It should be noted that despite injecting the vector into the vessels that perfuse the cirrhotic liver, we could detect transgene expression in extra-hepatic tissues, particularly the testes and spleen. The use of other routes of administration or other serotypes such as AAV5, 6 or 8 could result in a different bio-distribution. Off-targeted transgene expression from AAV1 could be avoided with the use of a liver-specific promoter. Interestingly, AAV1 vectors with a liver-specific promoter fail to express the transgene in HSCs and Kupffer cells efficiently. As activated HSCs are the major source of collagen, it could be desirable to target HSCs for the treatment of liver cirrhosis. This could be achieved with adenoviral vectors. 30, 31 Alternatively, hepatocytes could be transduced by AAV vectors to secrete therapeutic proteins that target HSCs. Altogether, our data show that AAV1 with a liver-specific promoter injected intra-arterially should be an ideal vector for long-term expression of therapeutic proteins in fibrotic livers.
MATERIALS AND METHODS
AAV vectors
dsAAV1-PBGD-Luc has a double-stranded DNA genome and expresses luciferase from a ubiquitous PBGD promoter (Figure 1a) . 20 ssAAV1-EhalbAAT-Luc has a single-stranded DNA genome and expresses luciferase from a liver-specific promoter. 27, 28 Both vectors contain the genome of AAV2 but were pseudotyped with the capsids from AAV1. Vectors were produced and purified as described by Paneda et al. 20 Titration of viral particles was performed by quantitative reverse transcription-PCR. 20 
Manipulation of animals
All procedures were performed following the regulations of the Animal Care Ethics Committee of the University of Navarra. Male Sprague-Dawley rats weighing 200-400 g were purchased from Harlan and maintained according to the institution's guidelines. Cirrhosis was induced by weekly intra-gastric administration of CCl 4 for 8 weeks or by intraperitoneal administration of 200 mg kg À1 of TAA three times per week for 7 weeks, as described previously. 10 Note that the protocol used to administer CCl 4 leads to constant levels of liver fibrosis for at least 33 weeks after initiation of the treatment. 10 Surgeries were performed on animals treated with inhalatory anesthetics. For inoculation of viral vectors, a laparatomy was performed and 200 ml of the indicated dose of virus in saline were inoculated into the hepatic artery, into the portal vein, into the bile duct or was injected into the liver at three different positions to achieve IH delivery. For hepatectomies, animals were fasted the day before surgery. The hepatectomy consisted of extraction of two lobules corresponding to two-thirds of the liver. Before extraction, the lobules were isolated with a thread to clamp the vessels and interrupt irrigation. Then, the two lobules were excised. When bleeding stopped, the abdominal cavity was closed and the wound was cleaned. All of the animals survived surgery.
Isolation of liver cells
Hepatocytes, HSCs and Kupffer-endothelial cells were isolated from cirrhotic male Sprague-Dawley rats as described by Sobrevals et al. 10 HSCs and Kupfferendothelial cells were separated in an inverted gradient. Cell viability was measured by Trypan blue exclusion and exceeded 90%. The purity of HSCs was greater than 99%, as assessed by fluorescence of retinoid-containing vacuoles under ultraviolet excitation. Rat primary hepatocytes, hepatic stellate cells and Kupffer/endothelial cells were grown as described by Wang et al. 33 and Friedman and Roll. 34 All culture media were supplemented with 10% fetal calf serum, 2 mmol l À1 glutamine and antibiotics.
